• The SALWEEN study showed significant improvements in vision and retinal health
  • More than 60% of Asian patients with polypoidal choroidal vasculopathy (PCV), an aggressive subtype of nAMD, treated with Vabysmo showed no signs of polypoidal lesions
  • By the end of year two, more than 60% of patients were on an extended 20-week treatment interval, reducing treatment burden
  • Vabysmo was well tolerated with a consistent long-term safety profile